METACAM ANTI-INFLAMMATORY ORAL SUSPENSION FOR DOGS

Country: Australia

Language: English

Source: APVMA (Australian Pesticides and Veterinary Medicines Authority)

Active ingredient:

MELOXICAM

Available from:

Boehringer Ingelheim Animal Health Australia Pty. Ltd.

INN (International Name):

meloxicam(1.5mg/mL)

Pharmaceutical form:

ORAL SOLUTION/SUSPENSION

Composition:

MELOXICAM UNGROUPED Active 1.5 mg/ml

Units in package:

100mL; 10mL; 180mL; 32mL

Class:

VM - Veterinary Medicine

Therapeutic group:

DOG | BITCH | CASTRATE | PUPPY

Therapeutic area:

MUSCULOSKELETAL SYSTEM

Therapeutic indications:

ANTI-INFLAMMATORY AGENT | ANTIPYRETIC | BONE SORENESS | BRUISING | BURSITIS | INFLAMMATORY RHEUMATIC ARTHRIT | JOINT DISEASE | LIGAMENT SPRAINS | MUSCLE SORENESS | OSTEOARTHRITIS | PLATELET ACTIVITY | RHEUMATISM | SPRAINS | STRAINS | TENDON SPRAINS | TRAUMATIC SWELLING

Product summary:

Poison schedule: 4; Withholding period: WHP: N/A; Host/pest details: DOG: [ANTI-INFLAMMATORY AGENT]; For the alleviation of inflammation and pain in both acute and chronic musculoskeletal disorders.Do not administer to pregnant or lactating bitches in the last third of pregnancy.

Authorization status:

Registered

Authorization date:

2023-07-01

Patient Information leaflet

METACAM ANTI-INFLAMMATORY ORAL SUSPENSION FOR DOGS
49655/135215
Product Name:
APVMA Approval No:
Label Name:
METACAM ANTI-INFLAMMATORY ORAL SUSPENSION FOR DOGS
Signal Headings:
PRESCRIPTION ANIMAL REMEDY
KEEP OUT OF REACH OF CHILDREN
FOR ANIMAL TREATMENT ONLY
READ SAFETY DIRECTIONS
Constituent
Statements:
1.5 mg/mL MELOXICAM
Claims:
Metacam Oral Suspension is a non-steroidal anti-inflammatory drug
(NSAID) for use in
dogs. It is indicated for the alleviation of inflammation and pain in
both acute and chronic
musculoskeletal disorders such as discospondylosis, arthropathy and
soft tissue injuries.
Net Contents:
10 mL
32 mL
100 mL
180 mL
Directions for Use:
Restraints:
Contraindications:
This product is contraindicated for use in pregnant or lactating
animals.
This product is contraindicated for use in animals less than 6 weeks
of age.
The use of the product is contraindicated in animals suffering from
cardiac, hepatic or
clinical renal disease. This is also the case where there is the
possibility of gastrointestinal
ulceration or bleeding, or where there is evidence of a haemorrhagic
disorder or individual
hypersensitivity to the product.
Precautions:
Metacam Oral Suspension should not be administered concurrently with
steroidal or other
non-steroidal anti-inflammatory drugs, diuretics, aminoglycoside
antibiotics, anti-coagulant RLP APPROVED
agents or substances with high protein binding as they may compete for
binding and thus
lead to toxic effects.
Pre-treatment with anti-inflammatory drugs may result in additional or
increased adverse
effects and accordingly a treatment-free period with such drugs should
be observed for at
least 24 hours before commencement with Metacam Oral Suspension.
The treatment-free period, however, should take into account the
pharmacokinetic
properties of the drugs used previously.
As for all NSAIDs use in debilitated aged animals may involve
additional risk. If use in such
animals cannot be avoided careful clinical management may be required.
Avoid use in any dehydrated, hypovolaemic or

Summary of Product characteristics

CS: 1.7.2
Page:
1
MATERIAL SAFETY DATA SHEET
4
of
Infosafe No™
LQ1I8
September 2012
ISSUED by BOEHRING
Issue Date :
METACAM® ANTI-INFLAMMATORY ORAL SUSPENSION FOR DOGS
Product Name :
Not classified as hazardous
1. IDENTIFICATION OF THE MATERIAL AND SUPPLIER
METACAM® ANTI-INFLAMMATORY ORAL SUSPENSION FOR DOGS
PRODUCT NAME
Boehringer Ingelheim Pty. Limited
COMPANY NAME
78 Waterloo Rd North Ryde
NSW 2113 Australia
ADDRESS
1800 038 037
EMERGENCY TEL.
Tel: [phone]
Fax: [phone]
TELEPHONE/FAX
NUMBER
[e-mail]
EMAIL
Metacam Oral Suspension is a non-steroidal anti-inflammatory drug
(NSAID) for
use in dogs. It is indicated for the alleviation of inflammation and
pain in
both acute and chronic musculoskeletal disorders such as
disco-spondylosis,
arthrothapy and soft tissue injuries.
RECOMMENDED USE
2. HAZARDS IDENTIFICATION
Not classified as hazardous
NON-HAZARDOUS SUBSTANCE.
NON-DANGEROUS GOODS.
Hazard classification according to the criteria of NOHSC.
Dangerous goods classification according to the Australia Dangerous
Goods
Code.
HAZARD
CLASSIFICATION
3. COMPOSITION/INFORMATION ON INGREDIENTS
Each mL contains 1.5mg meloxicam; one drop contains 0.05 mg meloxicam.
COMPOSITION,
INFORMATION ON
INGREDIENTS
NAME
CAS
PROPORTION
INGREDIENTS
Ingredients determined
not to be hazardous
Balance
Meloxicam
(4-hydroxy-2-methyl-N-
(5-methyl-2-thiazolyl)-
2H-1,2-benzothiazine-3-
carboxamide-1,1-dioxide
)
71125-38-7
1.5mg/mL
4. FIRST AID MEASURES
No special precautions required. However, if inhaled, remove affected
person
from contaminated area. Keep at rest until recovered. If symptoms
persist seek
medical attention.
INHALATION
Do not induce vomiting. Wash out mouth thoroughly with water. If
symptoms
develop seek medical attention.
INGESTION
Wash affected area thoroughly with soap and water. If symptoms develop
seek
medical attention. Contact a physician immediately and show the packet
insert
or label to the physician.
SKIN
If in eyes, hold eyelids apart and flush the eyes continuously with